Amphotericin B (MAT2203)
Small molecule
Evidence outlook · program status
On hold (2024-10-31), as a strategic decision by the sponsor
Matinas ceased all product development in October 2024 after partnership talks ended and seeks a partner or buyer for MAT2203; the Phase 3 ORALTO trial never started. The trials below are the program's evidence history; no evidence signal is assigned while development is paused.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
EnACT3 NCT05541107 · Cryptococcal Meningitis Registry: NCT05541107 | 3 | Survival (2 weeks) 2024-10 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent